Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-200c mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
miR-200c mimic is a synthetic, double-stranded RNA oligonucleotide designed to replicate the function of the endogenous microRNA miR-200c. It acts as a tumor suppressor by inhibiting the epithelial-to-mesenchymal transition (EMT) through the downregulation of key transcription factors and proteins, including ZEB1, ZEB2, N-cadherin, TrkB, and Bmi1. Preclinical studies have explored its potential in treating various cancers, such as lung, pancreatic, and breast cancer, as well as endometriosis. Delivery strategies often involve liposomal or polymeric nanoparticle formulations to enhance stability and cellular uptake. Currently, it is primarily utilized as a research reagent and has not entered formal clinical development under a proprietary name.
- Other names
- miR-200c mimicmiR200c mimicmiR 200c mimicsynthetic miR-200c duplex
02
Targets
CDH2 (N-cadherin)ZEB2 (Zinc finger E-box-binding homeobox 2)BMI1 (Polycomb complex protein BMI-1)ZEB1 (Zinc finger E-box-binding homeobox 1)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on miR-200c mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-200c mimic.